Regen BioPharma, Inc. (RGBP)

Regen BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 8, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Market Capitalization	0	1	1	6	33	130
Market Cap Growth	-96.13%	-48.33%	-83.75%	-80.65%	-74.88%	59229.10%
Enterprise Value	1	2	2	7	34	132
Last Close Price	0.00	0.01	0.10	0.90	4.88	22.82
PE Ratio	-	-	-	6.18	14.69	-
PS Ratio	0.24	2.25	4.35	26.75	138.87	760.54
PB Ratio	-0.01	-0.08	-0.20	-1.24	-4.07	-9.65
EV/Sales Ratio	4.36	6.62	7.13	29.34	145.32	773.60
Debt / Equity Ratio	-0.18	-0.19	-0.15	-0.15	-0.16	-0.27
Net Debt / Equity Ratio	-0.18	-0.18	-0.15	-0.12	-0.15	-0.21
Asset Turnover	1.10	1.09	0.92	0.52	0.27	0.26
Quick Ratio	0.05	0.04	0.02	0.02	0.04	0.06
Current Ratio	0.05	0.04	0.03	0.03	0.04	0.07
Return on Assets (ROA)	-252.85%	-97.12%	-101.33%	-94.09%	-23.97%	-18.79%
Return on Capital Employed (ROCE)	16.20%	5.40%	8.00%	13.90%	4.20%	1.50%
Earnings Yield	-1273.56%	-239.77%	-64.96%	18.27%	7.47%	-5.20%
Buyback Yield / Dilution	-507.33%	-186.14%	-16.21%	-12.79%	-56.19%	-113.61%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 7, 2026

Data Sources Report a data error